Eyenovia (NASDAQ:EYEN) Shares to Reverse Split on Monday, February 3rd

Shares of Eyenovia, Inc. (NASDAQ:EYEN) are going to reverse split before the market opens on Monday, February 3rd. The 1-80 reverse split was announced on Tuesday, January 28th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 31st.

Eyenovia Stock Down 34.7 %

EYEN stock opened at $0.04 on Thursday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $4.15 million, a PE ratio of -0.05 and a beta of 1.31. Eyenovia has a 1-year low of $0.04 and a 1-year high of $2.57. The business’s 50 day simple moving average is $0.09 and its 200 day simple moving average is $0.46.

Eyenovia (NASDAQ:EYEN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter last year, the firm posted ($0.18) EPS. As a group, research analysts anticipate that Eyenovia will post -0.5 EPS for the current year.

Wall Street Analysts Forecast Growth

EYEN has been the topic of a number of research reports. LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Eyenovia in a report on Monday, November 18th. Brookline Capital Management reiterated a “hold” rating on shares of Eyenovia in a research report on Friday, November 15th. HC Wainwright downgraded Eyenovia from a “buy” rating to a “neutral” rating and cut their target price for the company from $12.00 to $2.00 in a research report on Monday, November 18th. Finally, William Blair reiterated a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th.

Institutional Trading of Eyenovia

Institutional investors have recently modified their holdings of the stock. Nations Financial Group Inc. IA ADV lifted its position in shares of Eyenovia by 78.6% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock worth $47,000 after buying an additional 40,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eyenovia during the 2nd quarter worth $26,000. Financial Management Network Inc. bought a new stake in shares of Eyenovia during the 3rd quarter worth $39,000. Finally, Geode Capital Management LLC lifted its position in shares of Eyenovia by 36.6% during the 3rd quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after buying an additional 149,471 shares during the last quarter. 25.84% of the stock is currently owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.